In Massachusetts, TEPHA Inc. completed a buy-out of its royalty obligation to Metabolix, Inc., its former licensor and parent company. TEPHA develops implantable medical devices based on biomaterials, including a biologic polymer called poly4hydroxybutyrate (P4HB) which is made through a fermentation process. Andrew Joiner, President and CEO of Tepha, told PR Newsire “The buy-out of our royalty obligation in conjunction with Metabolix was financially advantageous for both companies. Specifically for Tepha, the cash flow from our savings will help finance the continued development of our core technology as well as pre-clinical and clinical testing of new applications.” TEPHA plans on using its P4HB-based fibers to expand into collagen, antibiotic coatings and non-woven materials in new markets.
Latest article
Fishway hooks Multus to jointly accelerate cultivated fish
In the United Kingdom, Fishway and Multus Biotechnology have partnered to bring cultivated fish to market faster.
The pact will leverage Fishway's expertise in...
Pirelli unveils biobased tires for Range Rovers
In Milan, tire manufacturer Pirelli has launched the first standard production tire for the global market made with over 70% biobased and recycled materials,...
MIT students design 3D printer that converts home food waste into knick-knacks
In Boston, Massachusetts Institute of Technology students Biru Cao and Qiqing Wang have developed an AI-drive desktop 3D printer that converts household food waste...